Clinical

Dataset Information

0

Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer


ABSTRACT: This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.

DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2385325 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2729957 | ecrin-mdr-crc
2021-04-07 | GSE149206 | GEO
| 2303741 | ecrin-mdr-crc
| 2346468 | ecrin-mdr-crc
| 2329228 | ecrin-mdr-crc
| 2559 | ecrin-mdr-crc
2010-03-18 | E-GEOD-18392 | biostudies-arrayexpress
2021-07-19 | GSE178706 | GEO
| 2310012 | ecrin-mdr-crc
| PRJNA740039 | ENA